Imbian Lab

History

2022: Investing 400 million rubles in infection detection systems

As it became known in February 2022, the Novosibirsk medical test developer Imbian Lab will invest 400 million rubles in infection detection systems, including coronavirus COVID-19. Production of new products is planned to be established in the special economic zone (SEZ) Technopolice Moscow.

The company will produce medical tests designed to detect a large number of infections and abnormalities in human health. Including 15 types of test systems for the presence of COVID-19. It is planned that the enterprise will produce about 12 million units of products per month, "said Vladimir Efimov, deputy mayor of Moscow for economic policy and property and land relations, whose words are quoted on the official website of the capital's mayor.

Imbian Lab invests 400 million rubles in infection detection systems

Medical test systems that will be produced at the enterprise are focused on the market of Moscow and the regions. Some products are planned to be exported.

The total area of ​ ​ the new enterprise is 2.5 thousand square meters. Half of the territory is occupied by "clean premises" with a laboratory, a production site for research, development and testing. The second half was taken for labeling and packaging of finished products, auxiliary work.

Imbian Lab specializes in the development and supply of diagnostic kits for enzyme immunoenzyme (ELISA), immunochromatographic (ICA) methods, as well as the polymerase chain reaction (PCR) method. The supplier's portfolio includes express tests for antigen and antibodies to coronavirus SARS-CoV-2, medical tests for hepatitis C, urogenital and TORCH infections under the Imbian brand. The company is developing its own immunocytes - test systems for the simultaneous detection in the serum and plasma of human blood of antibodies and antigens to the causative agents of various types of infections.^[1]

Notes